NCT00283933View on ClinicalTrials.gov

A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 9, 2006

Primary Completion Date

March 12, 2008

Study Completion Date

March 12, 2008

Conditions
Fabry Disease
Interventions
DRUG

migalastat HCl

Trial Locations (2)

75015

Paris

NW3 2QG

London

Sponsors
All Listed Sponsors
lead

Amicus Therapeutics

INDUSTRY